Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

Basit Öğe Kaydı
dc.authoridCosar, Rusen/0000-0002-7953-8887
dc.authoridEralp, Yesim/0000-0001-9603-4755
dc.authoridCosar, Rusen/0000-0002-7953-8887
dc.authoridCicin, Irfan/0000-0002-7584-3868;
dc.authorwosidCosar, Rusen/AAC-4045-2020
dc.authorwosidEralp, Yesim/AAD-7194-2020
dc.authorwosidCosar, Rusen/GQP-7875-2022
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.authorwosidküçücük, seden/JWP-5854-2024
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidSaglam, Esra Kaytan/AAE-7436-2020
dc.contributor.authorSaip, Pinar
dc.contributor.authorCicin, Irfan
dc.contributor.authorEralp, Yesim
dc.contributor.authorKaragol, Hakan
dc.contributor.authorKucucuk, Seden
dc.contributor.authorAlas, Rusen Cosar
dc.contributor.authorYavuz, Ekrem
dc.date.accessioned2024-06-12T10:55:10Z
dc.date.available2024-06-12T10:55:10Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground To identify the candidates for prophylactic cranial radiotherapy (PCI) among the patients with early and advanced-stage breast cancer. Methods The demographic, pathologic and clinical features and survival results of 182 brain metastatic breast cancer patients treated with cranial radiotherapy were examined. Results Early stage patients who progressed with isolated brain metastasis had longer survival (13 months vs. 4 months P = 0.006). Lobular/mixed type histology (P = 0.033), high nuclear (P = 0.046) and high histological grade (P = 0.034) were the prognostic factors for isolated brain metastases. The most significant factor for the time to brain metastasis was the number of involved of lymph nodes (P = 0.004). In 60% of 148 patients with metastatic breast cancer, a progression with isolated brain metastasis was developed while the systemic disease was under control. Isolated brain metastasis progression was related to the presence of the hepatic metastasis at the first relapse (P = 0.001) and with ErbB-2 overexpression (P = 0.034). The time to the brain metastasis from the first extracerabral metastasis was associated with the high nuclear grade (P = 0.040) and with chemoresistance (P = 0.037). The median survival time after the brain metastases in chemosensitive patients was longer than in chemoresistant patients (8 months vs. 3 months P = 0.044). In chemoresistant patients (P = 0.0028) and/or in triple negative patients (P = 0.05) the development of the brain metastasis was early and the survival after brain metastasis was short. Discussions Since there is a tendency to early brain metastasis in early stage patients with high-grade, lobular/mixed type histology tumors and with a high number of involved lymph nodes, the value of PCI can be explored in these patients by a well designed prospective trial. Advanced stage chemosensitive patients with ErbB-2 over-expression and/or with hepatic metastasis at their first relapse may be candidates for PCI. There is no place for PCI in chemoresistant and triple-negative breast cancer patients.en_US
dc.identifier.doi10.1007/s11060-008-9769-0
dc.identifier.endpage251en_US
dc.identifier.issn0167-594X
dc.identifier.issn1573-7373
dc.identifier.issue2en_US
dc.identifier.pmid19099196en_US
dc.identifier.scopus2-s2.0-67349083524en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage243en_US
dc.identifier.urihttps://doi.org/10.1007/s11060-008-9769-0
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19322
dc.identifier.volume93en_US
dc.identifier.wosWOS:000266141700010en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Neuro-Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectBrain Metastasisen_US
dc.subjectProphylactic Cranial Irradiationen_US
dc.subjectNervous-System Metastasesen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectTrastuzumaben_US
dc.subjectCarcinomaen_US
dc.subjectReceptoren_US
dc.subjectTherapyen_US
dc.subjectIrradiationen_US
dc.subjectInvolvementen_US
dc.subjectEpirubicinen_US
dc.subjectSurvivalen_US
dc.titleIdentification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu